(300 WORDS MAX.) Neuronascent is developing neuro-regenerative, small molecule agents that promote new neuron growth in key regions of the brain that correlate with the reversal of cognitive impairment. Neuronascent aims to administer NNI-362 to aged Alzheimer's patients in order to halt or reverse the disease progression by changing the morphology of the brain to increase the hippocampal volume that is directly correlated to the extent of cognitive impairment in Alzheimer's disease. This Phase Ia study in aged healthy volunteers will be critical to ensure the safety of aged patients.